当前位置: 首页 >> 检索结果
共有 3390 条符合本次的查询结果, 用时 8.5001435 秒

561. Higher Work of Breathing During Exercise in Heart Failure With Preserved Ejection Fraction.

作者: Nicolas Villarraga.;Brit Warner.;Eric J Bruhn.;Shane M Hammer.;Thomas G Bissen.;Thomas P Olson.;Joshua R Smith.
来源: Chest. 2023年163卷6期1492-1505页
It is unknown if pulmonary alterations in heart failure with preserved ejection fraction (HFpEF) impact respiratory mechanics during exercise.

562. Emphysema Quantifications With CT Scan: Assessing the Effects of Acquisition Protocols and Imaging Parameters Using Virtual Imaging Trials.

作者: Ehsan Abadi.;Giavanna Jadick.;David A Lynch.;W Paul Segars.;Ehsan Samei.
来源: Chest. 2023年163卷5期1084-1100页
CT scan has notable potential to quantify the severity and progression of emphysema in patients. Such quantification should ideally reflect the true attributes and pathologic conditions of subjects, not scanner parameters. To achieve such an objective, the effects of the scanner conditions need to be understood so the influence can be mitigated.

563. OSA and Subsequent Risk of Hospitalization With Pneumonia, Respiratory Infection, and Total Infection: The Atherosclerosis Risk in Communities Study.

作者: Pamela L Lutsey.;Islam Zineldin.;Jeffrey R Misialek.;Kelsie M Full.;Kamakshi Lakshminarayan.;Junichi Ishigami.;Logan T Cowan.;Kunihiro Matsushita.;Ryan T Demmer.
来源: Chest. 2023年163卷4期942-952页
OSA has been linked to microaspiration, systemic inflammation, and suboptimal immune function.

564. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.

作者: Matthew K Wynia.;Laurel E Beaty.;Tellen D Bennett.;Nichole E Carlson.;Christopher B Davis.;Bethany M Kwan.;David A Mayer.;Toan C Ong.;Seth Russell.;Jeffrey D Steele.;Heather R Stocker.;Adane F Wogu.;Richard D Zane.;Ronald J Sokol.;Adit A Ginde.
来源: Chest. 2023年163卷5期1061-1070页
Neutralizing monoclonal antibodies (mAbs) were authorized for the treatment of COVID-19 outpatients based on clinical trials completed early in the pandemic, which were underpowered for mortality and subgroup analyses. Real-world data studies are promising for further assessing rapidly deployed therapeutics.

565. Racial Disparities in Lung Cancer Stage of Diagnosis Among Adults Living in the Southeastern United States.

作者: Jennifer Richmond.;Megan Hollister Murray.;Cato M Milder.;Jeffrey D Blume.;Melinda C Aldrich.
来源: Chest. 2023年163卷5期1314-1327页
Black Americans receive a diagnosis at later stage of lung cancer more often than White Americans. We undertook a population-based study to identify factors contributing to racial disparities in lung cancer stage of diagnosis among low-income adults.

566. Incidence of Respiratory Pathogens in Naval Special Warfare Sea, Air, and Land Team Candidates With Swimming-Induced Pulmonary Edema.

作者: Benjamin A Sebreros.;Piotr Wisniewski.;Peter Lindholm.;Gilbert E Boswell.;Charles G Volk.
来源: Chest. 2023年163卷5期1185-1192页
Swimming-induced pulmonary edema (SIPE) is a respiratory condition frequently seen among Naval Special Warfare (NSW) trainees. The incidence of positive respiratory panel (RP) findings in trainees with a diagnosis of SIPE currently is unknown.

567. Cardiovascular Complications Are the Primary Drivers of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia.

作者: Ahmed Shebl Ali.;Daniya Sheikh.;Thomas R Chandler.;Stephen Furmanek.;Jiapeng Huang.;Julio A Ramirez.;Forest Arnold.;Rodrigo Cavallazzi.
来源: Chest. 2023年163卷5期1051-1060页
Hospitalized patients with SARS-CoV-2 community-acquired pneumonia (CAP) and associated comorbidities are at increased risk of cardiovascular complications. The magnitude of effect of cardiovascular complications and the role of prior comorbidities on clinical outcomes are not well defined.

568. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.

作者: Spyridon Fortis.;Pedro M Quibrera.;Alejandro P Comellas.;Surya P Bhatt.;Donald P Tashkin.;Eric A Hoffman.;Gerard J Criner.;MeiLan K Han.;R Graham Barr.;Mehrdad Arjomandi.;Mark B Dransfield.;Stephen P Peters.;Brett A Dolezal.;Victor Kim.;Nirupama Putcha.;Stephen I Rennard.;Robert Paine.;Richard E Kanner.;Jeffrey L Curtis.;Russell P Bowler.;Fernando J Martinez.;Nadia N Hansel.;Jerry A Krishnan.;Prescott G Woodruff.;Igor Z Barjaktarevic.;David Couper.;Wayne H Anderson.;Christopher B Cooper.; .
来源: Chest. 2023年163卷3期502-514页
Bronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features.

569. Near Hanging: Evaluation and Management.

作者: Jon D Dorfman.
来源: Chest. 2023年163卷4期855-860页
Prior to the COVID-19 pandemic, the incidence of self-harm was already on the rise. Hanging/suffocation accounted for 50% of the increase in suicide attempts and remains the second leading cause of death from self-harm in the United States. Studies on the management of near-hanging patients are lacking, and most published literature is retrospective. Following airway and circulation assessment, clinical examination and imaging, namely CT angiography, remain the standard for identifying the injuries associated with near hanging: cervical spine fracture, blunt cerebrovascular injury, laryngeal injury, and injury to the trachea and oropharynx. These injuries, however, are uncommon, and each occur in < 5% of patients in most series. In a large series of critically ill near-hanging patients, > 50% survived to hospital discharge; however, cardiac arrest predicted a poor outcome. The management of asphyxia-related arrest remains controversial. Targeted temperature management has only been studied in a single large multicenter trial, which was retrospective. Given the significant selection bias of targeted temperature management in the treatment of the most ill patients, no firm recommendations can be made. Finally, for survivors, the underlying mental health issues must be addressed to avoid recurrent suicide attempts. Thirty percent of patients in a large near-hanging series were admitted for their second suicide attempt.

570. Development and Validation of a Risk Assessment Model for Pulmonary Nodules Using Plasma Proteins and Clinical Factors.

作者: Anil Vachani.;Stephen Lam.;Pierre P Massion.;James K Brown.;Michael Beggs.;Amanda L Fish.;Luis Carbonell.;Shan X Wang.;Peter J Mazzone.
来源: Chest. 2023年163卷4期966-976页
Deficiencies in risk assessment for patients with pulmonary nodules (PNs) contribute to unnecessary invasive testing and delays in diagnosis.

571. Evaluation of an In-Home Virtual Pulmonary Rehabilitation Program for Respiratory Patients Delivered in Response to the COVID Pandemic.

作者: Virginia C Huynh.;Evelyn Etruw.;Eli Bok.;Desi P Fuhr.;Michael K Stickland.
来源: Chest. 2023年163卷3期529-532页

572. Efzofitimod for the Treatment of Pulmonary Sarcoidosis.

作者: Daniel A Culver.;Shambhu Aryal.;Joseph Barney.;Connie C W Hsia.;W Ennis James.;Lisa A Maier.;Lucian T Marts.;Ogugua Ndili Obi.;Peter H S Sporn.;Nadera J Sweiss.;Sanjay Shukla.;Nelson Kinnersley.;Gennyne Walker.;Robert Baughman.
来源: Chest. 2023年163卷4期881-890页
Pulmonary sarcoidosis is characterized by the accumulation of immune cells that form granulomas affecting the lungs. Efzofitimod (ATYR1923), a novel immunomodulator, selectively binds neuropilin 2, which is upregulated on immune cells in response to lung inflammation.

573. Trends in Intensive Care Admissions and Outcomes of Stroke Patients Over 10 Years in Brazil: Impact of the COVID-19 Pandemic.

作者: Pedro Kurtz.;Leonardo S L Bastos.;Fernando G Zampieri.;Gabriel R de Freitas.;Fernando A Bozza.;Marcio Soares.;Jorge I F Salluh.
来源: Chest. 2023年163卷3期543-553页
The coronavirus 2019 (COVID-19) pandemic affected stroke care worldwide. Data from low- and middle-income countries are limited.

574. Response.

作者: Ryan C Maves.;Mary A King.
来源: Chest. 2022年162卷5期e290页

575. Where PICU Beds Are Lacking, the Model of "Extended NICU" May Help to Treat Infants and Small Toddlers Who Are Critically Ill, Even During the COVID-19 Pandemic.

作者: Nunzia Decembrino.;Eloisa Gitto.;Tiziana Fedeli.;Ferdinando Spagnuolo.;Luigi Orfeo.;Corrado Moretti.;Paola Cogo.;Nicola Pozzi.
来源: Chest. 2022年162卷5期e289-e290页

576. Response.

作者: Wesley H Self.;Allison P Wheeler.;James D Chappell.;Isaac Thomsen.;Jill M Pulley.;Jillian P Rhoads.;Gordon R Bernard.;Todd W Rice.
来源: Chest. 2022年162卷5期e285-e287页

577. COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON.

作者: Arturo Casadevall.;Jeffrey P Henderson.
来源: Chest. 2022年162卷5期e284-e285页

578. Late Treatment for COVID-19 With Convalescent Plasma.

作者: Jonathon W Senefeld.;Nigel S Paneth.;Rickey E Carter.;R Scott Wright.;DeLisa Fairweather.;Katelyn A Bruno.;Michael J Joyner.
来源: Chest. 2022年162卷5期e283-e284页

579. Limitations on PassItOn Design and Execution Should Temper Negative Conclusions.

作者: Shmuel Shoham.;Daniele Focosi.
来源: Chest. 2022年162卷5期e282-e283页

580. A 52-Year-Old Man With Chest Pain and Dyspnea.

作者: Charles G Murphy.;Jonathan M Goldstein.;Sepideh Besharati.;Serge Kobsa.;Mary M Salvatore.;Erika B Rosenzweig.;Matthew Ingham.;Armando Del Portillo.;Koji Takeda.;Subani Chandra.;David Furfaro.
来源: Chest. 2022年162卷5期e259-e264页
A 52-year-old man came to the cardiac surgery clinic for pulmonary thromboendarterectomy (PTE) evaluation. He had initially appeared at an outside hospital 1 year earlier, with chest pain and shortness of breath. He had no known chronic conditions. A CT pulmonary angiogram (CTPA) at that time showed a filling defect at the bifurcation of the main pulmonary artery. A transthoracic echocardiogram revealed mild mitral valve regurgitation, but otherwise the results were normal. As he was hemodynamically stable and not hypoxemic, he was treated solely by anticoagulation. Despite adhering to prescribed apixaban, he developed progressive dyspnea and reduced exercise tolerance over the subsequent year. A repeat CTPA performed 12 months after the initial presentation showed a persistent filling defect at the level of the pulmonary artery bifurcation, with a new extension now completely occluding the right main pulmonary artery. A pulmonary angiogram confirmed this complete occlusion, and right heart catheterization revealed precapillary pulmonary hypertension, with a mean pulmonary artery pressure of 50 mm Hg. His anticoagulation was transitioned to enoxaparin for presumed apixaban treatment failure, and an investigation for hypercoagulable conditions was initiated. His lupus anticoagulant test result was positive, but he did not meet the criteria for antiphospholipid syndrome because he was negative for anticardiolipin and β2-glycoprotein antibodies. Assays for antithrombin III, protein C, prothrombin gene, and factor V Leiden mutations produced normal results.
共有 3390 条符合本次的查询结果, 用时 8.5001435 秒